Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Vutrisiran Coverage | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - TennesseePolicy ID_CHS_54912026_1126

    Vutrisiran (Amvuttra) Coverage

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_54912026_1126 alerts

    Get alerted when Policy ID_CHS_54912026_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and reauthorization for vutrisiran in adults with hereditary transthyretin-mediated amyloidosis polyneuropathy or wild-type/hereditary transthyretin-mediated amyloidosis cardiomyopathy, subject to clinical, diagnostic, prescriber, documentation, and non-combination criteria.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyVutrisiran (Amvuttra) Coverage
    Policy CodePolicy ID_CHS_54912026_1126
    Change TypeNo material clinical or coverage change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for vutrisiran with all applicable indication-specific criteria and required documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved covered indications
    12 monthsAuthorization period
    5Prohibited combination therapies
    3Tests for scintigraphy-proven ATTR-CM

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18 years
    Minimum patient age

    Coverage Criteria and Exclusions

    Initial therapy: hATTR-PN

    Authorization of 12 months may be granted when all criteria are met.

    Initial hATTR-PN criteria

    • Age: Member is 18 years of age or older.>= 18 years
    • Genetic confirmation: The diagnosis is confirmed by detection of a pathogenic variant in the TTR gene.Pathogenic TTR variant detected
    • Clinical manifestations: Member exhibits clinical manifestations of ATTR-FAP, such as amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.Clinical ATTR-FAP manifestations
    • Transplant status: Member is not a liver transplant recipient.No liver transplant
    • Non-combination use: The requested medication will not be used in combination with patisiran, eplontersen, acoramidis, tafamidis meglumine, or tafamidis.No prohibited concomitant therapy

    Initial therapy: ATTR-CM

    Authorization of 12 months may be granted when all criteria are met.

    Initial ATTR-CM criteria

    • Age: Member is 18 years of age or older.>= 18 years
    • Heart failure requirement: Member has a medical history of heart failure with at least one prior hospitalization for heart failure not due to arrhythmia or a conduction system disturbance treated with a permanent pacemaker, or exhibits clinical symptoms of heart failure at baseline, such as volume overload, dyspnea, fatigue, orthostatic hypotension, syncope, or peripheral edema.At least 1 qualifying hospitalization OR baseline heart failure symptoms
    • Diagnostic confirmation: ONE of

      • Biopsy-proven disease

    Indications other than the FDA-approved adult hATTR-PN and adult wild-type or hereditary ATTR-CM indications are considered experimental, investigational, and not medically necessary.

    Coverage for hATTR-PN is not available when the member is a liver transplant recipient.

    Coverage for ATTR-CM is excluded when the member has a prior or anticipated heart, liver, or other organ transplant or has undergone, or is expected to undergo, implantation of a left ventricular assist device (LVAD).

    Vutrisiran must not be used in combination with patisiran, eplontersen, acoramidis, tafamidis meglumine, or tafamidis. Use with any of these therapies is excluded from coverage.

    Vutrisiran is considered not medically necessary for indications other than the covered FDA-approved treatment of hATTR-PN in adults or ATTR-CM in adults.

    Initial Therapy Criteria

    Initial hATTR-PN therapy — ALL/ANY coverage logic

    Authorization of 12 months may be granted for initial hATTR-PN therapy when all criteria are met.

    Initial hATTR-PN criteria

    • Age: Member is 18 years of age or older.>= 18 years
    • Genetic confirmation: The diagnosis is confirmed by detection of a pathogenic variant in the TTR gene.
    • Clinical manifestations: Member exhibits clinical manifestations of ATTR-FAP, including amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.

    Continuation and Reauthorization Criteria

    Continuation therapy — requirements for 12-month reauthorization

    Authorization of 12 months may be granted for continued treatment when all applicable requirements are met.

    Reauthorization requirements

    • Ongoing coverage eligibility: Member continues to meet all requirements in the coverage criteria.All applicable initial criteria remain satisfied
    • Indication-specific response: ONE of

      • hATTR-PN: Member has demonstrated a beneficial response to treatment, such as improvement in neuropathy severity or rate of disease progression demonstrated by mNIS+7, Norfolk QoL-DN, PND score, FAP disease stage, or manual grip strength.Beneficial response compared with baseline

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for vutrisiran (Amvuttra). Initial authorization may be approved for 12 months when all applicable coverage criteria are met for an FDA-approved adult indication.

    • Adult hATTR-PN: treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
    • Adult ATTR-CM: treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis.
    • All applicable clinical, diagnostic, documentation, prescriber, and non-combination requirements must be satisfied.
    Prior Authorization

    Reauthorization Requires Demonstrated Benefit

    Reauthorization may be approved for 12 months when the member continues to meet all coverage requirements and medical records demonstrate benefit from vutrisiran compared with baseline.

    • hATTR-PN: document beneficial response, including improvement in neuropathy severity or disease progression measures.

    Policy Background

    Vutrisiran is covered for adults with hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN) and for adults with cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). ATTR-CM coverage requires confirmation through a biopsy-proven or technetium-labeled bone scintigraphy-proven pathway; for the scintigraphy pathway, systemic light chain amyloidosis must be excluded by demonstrating the absence of monoclonal proteins on the required serum and urine testing. Continued treatment requires documentation of benefit, stabilization, or slowed disease progression compared with baseline.

    Condition and Diagnostic Definitions

    hATTR-PN / ATTR-FAP
    Full nameHereditary transthyretin-mediated amyloidosis polyneuropathy
    Alternate terminologyTransthyretin-type familial amyloid polyneuropathy (ATTR-FAP)
    Diagnostic basisA pathogenic variant in the TTR gene must be detected, with clinical manifestations of ATTR-FAP.
    Clinical examplesAmyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.
    ATTR-CM
    Full nameCardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis
    Abbreviation
    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyVutrisiran (Amvuttra) Coverage
    Policy CodePolicy ID_CHS_54912026_1126
    Change TypeNo material clinical or coverage change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for vutrisiran with all applicable indication-specific criteria and required documentation.
    SourceLink
    On This Page
    Coverage Criteria and ExclusionsInitial Therapy CriteriaContinuation and Reauthorization CriteriaAuthorization, Documentation, and Denial RisksPolicy BackgroundCondition and Diagnostic Definitions
    Transthyretin amyloid deposits are present on analysis of a biopsy from a cardiac or noncardiac site.
  1. Transthyretin precursor proteins are confirmed by immunohistochemical analysis, mass spectrometry, tissue staining, or polarized light microscopy.
  2. Technetium-labeled bone scintigraphy-proven disease

    • Amyloid deposits are confirmed by technetium-labeled bone scintigraphy tracing.
    • Systemic light chain amyloidosis is ruled out by absence of monoclonal proteins on serum kappa/lambda free light chain ratio, serum protein immunofixation, and urine protein immunofixation.
  3. Transplant or LVAD status: Member does not have a prior or anticipated heart, liver, or other organ transplant or implantation of a left ventricular assist device.No qualifying transplant or LVAD
  4. Non-combination use: The requested medication will not be used in combination with patisiran, eplontersen, acoramidis, tafamidis meglumine, or tafamidis.No prohibited concomitant therapy
  5. Transplant status: Member is not a liver transplant recipient.
  6. Non-combination use: Vutrisiran will not be used in combination with patisiran, eplontersen, acoramidis, tafamidis meglumine, or tafamidis.
  7. Initial ATTR-CM therapy — ALL/ANY coverage logic

    Authorization of 12 months may be granted for initial ATTR-CM therapy when all criteria are met.

    Initial ATTR-CM criteria

    • Age: Member is 18 years of age or older.>= 18 years
    • Heart failure requirement: Member has at least one qualifying prior heart failure hospitalization or baseline clinical symptoms of heart failure.At least 1 qualifying hospitalization OR baseline symptoms
    • ONE of: diagnostic pathways

      • Biopsy-proven pathway

        • Transthyretin amyloid deposits are present on analysis of a cardiac or noncardiac biopsy.
        • Transthyretin precursor proteins are confirmed by immunohistochemical analysis, mass spectrometry, tissue staining, or polarized light microscopy.
      • Technetium-labeled bone scintigraphy-proven pathway

        • Amyloid deposits are confirmed by technetium-labeled bone scintigraphy tracing.
        • Systemic light chain amyloidosis is ruled out by absence of monoclonal proteins on serum kappa/lambda free light chain ratio, serum protein immunofixation, and urine protein immunofixation.

          All three tests are required.

    • Transplant or LVAD status: Member does not have a prior or anticipated heart, liver, or other organ transplant or implantation of a left ventricular assist device.
    • Non-combination use: Vutrisiran will not be used in combination with patisiran, eplontersen, acoramidis, tafamidis meglumine, or tafamidis.
  8. ATTR-CM: Member has demonstrated a clinically positive response to therapy, including improvement, stabilization, or slowing of disease progression, such as improvement in 6-minute walk distance, KCCQ-OS score, cardiovascular-related hospitalizations, NYHA classification, left ventricular stroke volume, or NT-proBNP level.Improvement, stabilization, or slowed progression compared with baseline
  9. Reauthorization — continued treatment and 12-month authorization

    Authorization of 12 months may be granted for continued treatment when all applicable requirements are met.

    All applicable reauthorization requirements

    • Ongoing eligibility: Member meets all requirements in the coverage criteria.All applicable coverage criteria remain satisfied
    • Applicable response requirement: ONE of

      • hATTR-PN response: Beneficial response is demonstrated compared with baseline, including improvement in neuropathy severity or rate of disease progression as shown by mNIS+7, Norfolk QoL-DN, PND score, FAP disease stage, or manual grip strength.Beneficial response compared with baseline
      • ATTR-CM response: Clinically positive response is demonstrated compared with baseline, including improvement, stabilization, or slowing of disease progression as shown by 6-minute walk distance, KCCQ-OS score, cardiovascular-related hospitalizations, NYHA classification, left ventricular stroke volume, or NT-proBNP level.Improvement, stabilization, or slowed progression compared with baseline
  10. ATTR-CM: document clinically positive response, including improvement, stabilization, or slowed disease progression.
  11. Documentation Required

    Qualified Prescriber Required

    Vutrisiran must be prescribed by, or prescribed in consultation with, an appropriately qualified specialist.

    • Eligible prescribers or consultants include a neurologist, geneticist, cardiologist, or physician specializing in amyloidosis treatment.
    Documentation Required

    Initial hATTR-PN Documentation

    Initial hATTR-PN requests must include documentation establishing both the genetic diagnosis and clinical disease manifestations.

    • Testing or analysis confirming a pathogenic variant in the TTR gene.
    • Medical records demonstrating clinical manifestations of transthyretin-type familial amyloid polyneuropathy (ATTR-FAP), such as amyloid deposition on biopsy, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.
    Documentation Required

    Initial ATTR-CM Documentation

    Initial ATTR-CM requests must include records confirming the heart failure history or baseline symptoms and diagnostic evidence of transthyretin amyloid cardiomyopathy.

    • Chart notes confirming prior hospitalization for heart failure or clinical symptoms of heart failure at baseline.
    • For biopsy-proven disease: tissue biopsy from a cardiac or noncardiac site showing transthyretin amyloid deposition and testing confirming transthyretin precursor proteins by immunohistochemistry, mass spectrometry, tissue staining, or polarized light microscopy.
    • For technetium-labeled bone scintigraphy-proven disease: scintigraphy tracing confirming amyloid deposits, plus serum kappa/lambda free light chain ratio, serum protein immunofixation, and urine protein immunofixation results showing no monoclonal proteins.
    Documentation Required

    Continuation hATTR-PN Documentation

    Continuation requests for hATTR-PN must include chart notes showing a beneficial response to vutrisiran compared with baseline.

    • Relevant evidence may include improvement in mNIS+7, Norfolk QoL-DN total score, PND score, FAP disease stage, manual grip strength, neuropathy severity, or rate of disease progression.
    Documentation Required

    Continuation ATTR-CM Documentation

    Continuation requests for ATTR-CM must include records showing a clinically positive response compared with baseline, including improvement, stabilization, or slowed disease progression.

    • Relevant evidence may include the 6-minute walk test, KCCQ-OS score, cardiovascular-related hospitalizations, NYHA classification, left ventricular stroke volume, or NT-proBNP level.
    Denial Risk

    Unapproved Indication May Be Denied

    Coverage is not medically necessary for indications outside the FDA-approved adult uses of vutrisiran.

    • Covered indications are adult hATTR-PN and adult cardiomyopathy associated with wild-type or hereditary ATTR-CM.
    • All other indications are considered experimental or investigational and not medically necessary.
    Denial Risk

    hATTR-PN Criteria Not Met

    An hATTR-PN request may be denied when any required coverage condition is not met.

    • Member is younger than 18 years of age.
    • Pathogenic TTR gene variant is not confirmed.
    • Clinical manifestations of ATTR-FAP are not documented.
    • Member is a liver transplant recipient.
    • Vutrisiran would be used with patisiran (Onpattro), eplontersen (Wainua), acoramidis (Attruby), tafamidis meglumine (Vyndaqel), or tafamidis (Vyndamax).
    Denial Risk

    ATTR-CM Criteria Not Met

    An ATTR-CM request may be denied when any required age, heart failure, diagnostic, transplant/device, or combination-therapy condition is not met.

    • Member is younger than 18 years of age.
    • There is no qualifying prior heart-failure hospitalization and no qualifying baseline heart-failure symptoms.
    • ATTR-CM is not confirmed by either biopsy-proven disease or technetium-labeled bone scintigraphy criteria.
    • For biopsy-proven disease, transthyretin amyloid deposits or confirmation of transthyretin precursor proteins is missing.
    • For scintigraphy-proven disease, amyloid deposits are not confirmed or systemic light-chain amyloidosis is not ruled out by serum kappa/lambda free light chain ratio, serum protein immunofixation, and urine protein immunofixation.
    • Member has a prior or anticipated heart, liver, or other organ transplant, or implantation of a left-ventricular assist device.
    • Vutrisiran would be used with patisiran (Onpattro), eplontersen (Wainua), acoramidis (Attruby), tafamidis meglumine (Vyndaqel), or tafamidis (Vyndamax).
    Documentation Required

    Prescriber Specialty Requirement

    Verify the prescriber specialty or document specialist consultation before submitting the request.

    • The prescriber or consultant must be a neurologist, geneticist, cardiologist, or physician specializing in amyloidosis treatment.
    ATTR-CM
    Covered populationAdults with wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy.
    Qualifying clinical contextA history of at least one qualifying heart failure hospitalization or clinical symptoms of heart failure at baseline is required.
    Diagnostic confirmationThe diagnosis must be confirmed through either a biopsy-proven pathway or a technetium-labeled bone scintigraphy-proven pathway.
    Technetium-labeled bone scintigraphy-proven disease
    Required imagingTechnetium-labeled bone scintigraphy tracing must confirm the presence of amyloid deposits.
    Systemic light chain amyloidosisMust be ruled out by showing the absence of monoclonal proteins.
    Serum testingSerum kappa/lambda free light chain ratio and serum protein immunofixation are required.
    Urine testingUrine protein immunofixation is required.
    Complete exclusion pathwayAll three monoclonal-protein tests—serum kappa/lambda free light chain ratio, serum protein immunofixation, and urine protein immunofixation—must show absence of monoclonal proteins.